Biologics License Application for tezepelumab submitted to FDA for treatment of patients with severe, uncontrolled asthma

Submission for this monoclonal antibody that blocks epithelial cytokine thymic stromal lymphopoietin is supported by data from PATHFINDER clinical program including NAVIGATOR trial which showed statistically significant reduction in annualized asthma exacerbation rate vs. placebo

Source:

Biospace Inc.